Burden of Cardiovascular Disease in Immune Checkpoint Inhibitor–Treated Patients: Reconciling Adjudicated and Coded Outcomes

BACKGROUND: There is growing recognition of the risk of cardiovascular (CV) events, particularly myocarditis, in the context of immune checkpoint inhibitor (ICI) therapy; however, true event rates in real-world populations and in the background of CV disease remain uncertain. OBJECTIVES: The authors...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondapalli, Lavanya, Hsia, Judith, Miller, Ronni, Flaig, Thomas W., Bonaca, Marc P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830208/
https://www.ncbi.nlm.nih.gov/pubmed/36636437
http://dx.doi.org/10.1016/j.jaccao.2022.09.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830208/
https://www.ncbi.nlm.nih.gov/pubmed/36636437
http://dx.doi.org/10.1016/j.jaccao.2022.09.003

Ejemplares similares